This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

MLV Announces Formation Of Advisory Board And Appointment Of Dr. Rahul Singhvi As Its Founding Director

NEW YORK, June 3, 2011 /PRNewswire/ -- McNicoll, Lewis & Vlak LLC (MLV), a boutique investment bank focused on providing independent financial advice and unique capital markets expertise to corporate and institutional clients in capital intensive industries announced today the formation of an MLV Advisory Board comprised of industry leaders with expertise and experience in a range of businesses relevant to MLV's goal of providing unique and efficient capital raising and growth solutions for its clients.  At the same time, it announced the appointment of Dr. Rahul Singhvi, former President & CEO of Novavax, Inc. (Nasdaq: NVAX), a development stage vaccine company, as MLV Advisory Board's founding director.

(Logo: http://photos.prnewswire.com/prnh/20100920/NY67927LOGO )

In making the announcement, Patrice McNicoll, CEO of MLV noted, "MLV's mission is to create a new paradigm on Wall Street.  As a leader in At-the-Market (ATM) issuance, we are already delivering to clients the most efficient and cost-effective means of raising equity capital in the public markets.  We are creating our Advisory Board to bring together innovative business leaders to help us continue to develop new and unique growth and capital solutions for both public and private companies in capital intensive sectors."

"We are extremely pleased to have attracted someone of Dr. Singhvi's stature to spearhead our Advisory Board efforts," added Dean Colucci, President of MLV.  "Dr. Singhvi has been a visionary and a business leader in the vaccine and pharmaceutical industry.  During his tenure as CEO of Novavax, he transformed Novavax from a distressed specialty pharmaceutical Company into a premier vaccine development company.  Under his leadership, Novavax rapidly advanced a robust pipeline of technologically innovative and important clinical and preclinical stage vaccine candidates.  With Dr. Singhvi's assistance, MLV will seek to expand the MLV Advisory Board to include other executives with a similar track record of growth, success, and innovation."

Dr. Singhvi commented that, "I was drawn to MLV because of its ability to think outside of the box in advising public companies and in keeping their best interests in mind.   Patrice has assembled a diverse and creative team of professionals to build MLV.  I am delighted to have the opportunity to join them and work together to develop MLV's strategic direction and future product offerings."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs